International Society for Peritoneal Dialysis practice recommendations: Prescribing high-quality goal-directed peritoneal dialysis. by Brown, EA et al.
Guidelines
International Society for Peritoneal
Dialysis practice recommendations:
Prescribing high-quality goal-directed
peritoneal dialysis
Edwina A Brown1 , Peter G Blake2, Neil Boudville3, Simon Davies4,5,
Javier de Arteaga6, Jie Dong7, Fred Finkelstein8, Marjorie Foo9,
Helen Hurst10, David W Johnson11, Mark Johnson12, Adrian Liew13,
Thyago Moraes14 , Jeff Perl15, Rukshana Shroff16,
Isaac Teitelbaum17 , Angela Yee-Moon Wang18
and Bradley Warady19
Lay summary
The International Society for Peritoneal Dialysis last published a guideline on prescribing peritoneal dialysis (PD) in 2006. This
focused on clearance of toxins and used a measure of waste product removal by dialysis using urea as an example. This
guideline suggested that a specific quantity of small solute removal was needed to achieve dialysis ‘adequacy’. It is now
generally accepted, however, that the well-being of the person on dialysis is related to many different factors and not just
removal of specific toxins. This guideline has been written with the focus on the person doing PD. It is proposed that dialysis
delivery should be ‘goal-directed’. This involves discussions between the person doing PD and the care team (shared
decision-making) to establish care goals for dialysis delivery. The aims of these care goals are (1) to allow the person doing
PD to achieve his/her own life goals and (2) to promote the provision of high-quality dialysis care by the dialysis team.
Key recommendations
1. PD should be prescribed using shared decision-making between the person doing PD and the care team. The aim is
to establish realistic care goals that (1) maintain quality of life for the person doing PD as much as possible by
enabling them to meet their life goals, (2) minimize symptoms and treatment burden while (3) ensuring high-quality
care is provided.
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2. The PD prescription should take into account the local country resources, the wishes and lifestyle con-
siderations of people needing treatment, including those of their families/caregivers’, especially if providing
assistance in their care.
3. A number of assessments should be used to help ensure the delivery of high-quality PD care.
a. Patient reported outcome measures – this is a measure of how a person doing PD is experiencing life and his/her
feeling of well-being. It should take into account the person’s symptoms, impact of the dialysis regimen on the
person’s life, mental health and social circumstances.
b. Fluid status is an important part of dialysis delivery. Urine output and fluid removed by dialysis both contribute
to maintaining good fluid status. Regular assessment of fluid status, including blood pressure and clinical
examination, should be part of routine care.
c. Nutrition status should be assessed regularly through evaluation of the patient’s appetite, clinical examination,
body weight measurements and blood tests (potassium, bicarbonate, phosphate, albumin). Dietary intake of
potassium, phosphate, sodium, protein, carbohydrate and fat may need to be assessed and adjusted as well.
d. Removal of toxins. This can be estimated using a calculation called Kt/Vurea and/or creatinine clearance. Both are
measures of the amount of dialysis delivered. There is no high-quality evidence regarding the need or benefit
associated with the achievement of a specific target value for these measures.
4. The amount of kidney function that continues to remove waste products and the remaining urine volume should
be known for all individuals doing PD. Management should focus on preserving this as long as possible.
5. For some people who require dialysis and who are old, frail or have a poor prognosis, there may be a quality of life
benefit from a reduced dialysis prescription to minimize the burden of treatment.
6. In low and lower middle-income countries, every effort should be made to conform to the framework of these
statements, taking into account resource limitations.
7. The principles of prescribing and assessing delivery of high-quality PD to children are the same as for adults. In all
cases, the PD prescription should be designed to meet the medical, mental health social and financial needs of the
individual child and family
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Background
The International Society for Peritoneal Dialysis (ISPD)
last published guidelines on prescribing peritoneal dialysis
(PD) in 2006.1 These focused primarily on targets for small
solute removal (Kt/Vurea and creatinine clearance) and
ultrafiltration. Even though the recommendations in that
guideline started with the statement, ‘Adequacy of dialysis
should be interpreted clinically rather than by targeting
only solute and fluid removal’, the guideline has often been
interpreted as stating that there must be a minimum small
solute removal target. Indeed, in some healthcare settings,
delivery of PD has focused on achieving the small solute
targets suggested in the 2006 guideline without taking into
consideration the impact of increasing dialysis exchanges
or hours on a cycling machine on a person’s quality of life.
Since 2006, those in need of dialysis have changed con-
siderably with increasing multimorbidity associated with
higher proportions of people with diabetes and/or in older age
groups. There is therefore increasing realization that dialysis is
only one component of care affecting outcomes (see Figure 1).
The need for a change in emphasis of care was the focus
of discussion at the Kidney Disease Improving Global Out-
comes Controversies Conference on Dialysis Initiation,
Modality Choice & Prescription in January 2018. At this
meeting, it was proposed that there should be a change in
terminology from ‘adequate’ dialysis to ‘goal-directed’ dia-
lysis defined as ‘using shared decision-making between the
patient and care team to establish realistic care goals that will
allow the patient to meet his/her own life goals and allow the
clinician to provide individualized, high quality dialyis
care’.2 This approach would require multiple measures and
goals to be considered when assessing quality of dialysis,
including symptoms, individual experiences and goals, resi-
dual kidney function, volume status, biochemical measures,
nutritional status, cardiovascular function, small solute clear-
ance and sense of well-being and satisfaction2 (Table 1).
This goal-directed approach concurs with the findings
from the Standardised Outcomes in Nephrology – PD ini-
tiative (https://songinitiative.org/projects/song-pd/), which
identified core outcomes for PD chosen by patients, care-
givers and healthcare professionals.3 These core outcomes
were PD infection, cardiovascular disease, mortality, PD
failure and life participation.4 There is no evidence that
small solute clearance on its own directly affects these core
outcome measures, except for a small proportion of indi-
viduals in whom transfer from PD to HD has been attrib-
uted to insufficient small solute removal.5,6 Otherwise, PD
infection and cardiovascular disease have already been
addressed by recent ISPD guidelines.7–10
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Given these changes in clinical emphasis, the Guideline
Committee of the ISPD invited a group of globally repre-
sentative nephrologists to compose new practice recom-
mendations for prescribing high-quality, goal-directed
PD. These recommendations are summarized in this article
with the underlying thought processes and/or evidence in
the accompanying manuscripts in this PDI supplement.
Evidence has been graded using the Grading of Recom-
mendations Assessment, Development and Evaluation
(GRADE) system for classification of the level of certainty
of the evidence and grade of recommendations in clinical
guideline reports.11,12 Within each recommendation, the
strength of the recommendation is indicated as Level 1
(We recommend), Level 2 (We suggest) or not graded, and
the certainty of the supporting evidence is shown asA (high
certainty), B (moderate certainty), C (low certainty) or D
(very low certainty). We have taken the position to label
statementswith low certainty evidence (2C, 2D) as practice
points
Headline recommendations
The aim of high-quality goal-directed dialysis is to provide
the best health outcome possible for an individual on PD in
terms of maintaining their clinical well-being, quality of
life, ability to meet life goals and at the same time minimize
treatment burden. The following headline recommenda-
tions are derived from the accompanying papers
1. PD should be prescribed using shared decision-making
between the person doing PD/ their caregivers and the
care team with the aim of achieving realistic care goals
to maximize quality of life and satisfaction for the
individual, minimize their symptoms and provide high
quality care (practice point).
Blake PG and Brown EA. Person-centered peritoneal
dialysis prescription and the role of shared decision
making. Perit Dial Int. Epub ahead of print 2020.
DOI: 10.1177/0896860819893803
2. PD can be prescribed in a variety of ways and should
take into account local resources, the person’s wishes
regarding lifestyle and the family’s/caregivers’ wishes
if they are providing assistance (practice point).
Wang AY-M, Zhao J, Bieger B, et al. on behalf of
PDOPPS dialysis prescription and fluid manage-
ment working group. International Comparison of
Peritoneal Dialysis Prescriptions from the Perito-
neal Dialysis Outcomes and Practice Patterns
Study (PDOPPS). Perit Dial Int. Epub ahead of
print 2020. DOI: 10.1177/0896860819895356
3. High-quality PD prescription should be guided by a
number of assessments encompassing the
person’s well-being and life participation, volume sta-
tus, nutritional status, anaemia management, small
solute removal and bone and mineral management.
3.1. Health-related quality of life
The person’s perception of their health-related
quality of life should be assessed routinely.
This should take into account assessment
of symptoms, the impact of dialysis treat-
ment prescription on life participation and
psychosocial status. Appropriate adjust-
ments in care should be made based on
these assessments (practice point).
Finkelstein FO and Foo MWY. Health-related
quality of life and adequacy of dialysis for
the individual maintained on peritoneal dia-
lysis. Perit Dial Int. Epub ahead of print
2020. DOI: 10.1177/0896860819893815
3.2. Volume status
a) High-quality PD prescription should aim
to achieve and maintain clinical euvolae-
mia taking residual kidney function and
its preservation into account, so that both
fluid removal from peritoneal ultrafiltra-
tion and urine output are considered and
residual kidney function is not compro-
mised (practice point).
Table 1. Factors affecting outcomes of people on peritoneal
dialysis.
Factor Impact
Multimorbidity Symptoms
Polypharmacy
Impaired physical function
Impaired cognitive function
Protein energy wasting
Age Impaired physical function
Impaired cognitive function
Protein energy wasting
Falls
Dementia/Delirium
Frailty
Dialysis-related Symptoms
Polypharmacy
Volume status – potential volume overload or
depletion
Poor appetite
Protein energy wasting
Burden of dialysis
Fatigue and malaise
Pruritus
Insomnia
Infections
Psychosocial Depression
Anxiety
Financial stress
Social support
Loss of employment
Reduced time for life participation
4 Peritoneal Dialysis International XX(X)
b) Bloodpressure should be included as one of
the key objective parameters in assessing
quality of PD prescription. However, there
is currently no evidence for a specific blood
pressure target in PD (practice point).
c) Regular assessment of volume status
including blood pressure and clinical
examination should be part of the routine
clinical care (practice point).
WangAY-M,Dong J, Xu X, et al. Volumemanage-
ment as a key dimension of a high-quality PD
prescription. Perit Dial Int. Epub ahead of
print 2020. DOI: 10.1177/0896860819895365
3.3. Nutritional status
a) Nutritional status should be regularly
assessed and monitored with attention to
appetite and dietary protein intake to
maintain a normal nutrition status with
restriction of phosphorus, sodium and
potassium as indicated (practice point).
b) Biochemical plasma markers including
potassium, bicarbonate, albumin, phos-
phate should be regularly measured as
markers of nutrition (practice point).
Glavinovic T, Hurst H, Hutchison A, et al. Pre-
scribing high-quality peritoneal dialysis:
moving beyond urea clearance. Perit Dial
Int. Epub ahead of print 2020. DOI:
10.1177/0896860819893571
3.4. Small solute clearance
a) Small solute clearance should be routinely
measured using Kt/Vurea or creatinine
clearance to provide a quantitative mea-
sure of the amount of dialysis delivered.
This can guide the amount of dialysis pre-
scribed, while recognizing the limitations
of accuracy of these measurements in indi-
viduals (practice point).
b) There is no specific clearance target that
guarantees sufficient dialysis for an indi-
vidual. Increasing small solute clearance
to a Kt/V > 1.7 may improve uraemia-
related symptoms, if present, but there is
only low certainty evidence showing that
increasing urea clearance has any impact
on quality of life, technique survival or
mortality (practice point).
c) The presence of residual kidney function at
the start of PD may enable individuals to
start on a low dose prescription that may
be increased incrementally as residual kid-
ney function declines or as clinically indi-
cated.Thismayallowpatientsmore time for
life participation, less treatment burden and
better quality of life (practice point).
d) If symptoms, nutrition and volume are all
controlled, no PD prescription change is
needed for the sole purpose of reaching
an arbitrary clearance target (practice
point).
Boudville N and Moraes TP. 2005 Guidelines on
targets for solute and fluid removal in adults
being treated with chronic peritoneal dialy-
sis: 2019 Update of the literature and revi-
sion of recommendations. Perit Dial Int.
Epub ahead of print 2020. DOI: 10.1177/
0896860819898307
Davies SJ and Finkelstein FO. Accuracy of the
estimation of V and the implications this has
when applying Kt/Vurea for measuring dialy-
sis dose in peritoneal dialysis. Perit Dial Int.
Epub ahead of print 2020. DOI: 10.1177/
0896860819893817
Blake PG, Dong J, Davies SJ. Incremental peri-
toneal dialysis. Perit Dial Int. Epub ahead of
print 2020. DOI: 10.1177/0896860819895362
4. Residual kidney function should be determined for all
individuals doing PD and management should focus on
preserving this function (practice point).
Chen CH, Perl J and Teitelbaum I. Prescribing high-
quality peritoneal dialysis: The role of preserving
residual kidney function. Perit Dial Int. Epub ahead
of print 2020. DOI: 10.1177/0896860819893821
5. For some individuals, particularly those who are old,
frail or have a poor prognosis, there may be a quality of
life benefit from a modified dialysis prescription to
minimize the burden of treatment (practice point).
Brown EA and Hurst H. Delivering peritoneal dialysis
for the multimorbid, frail and palliative patient.
Perit Dial Int. Epub ahead of print 2020. DOI:
10.1177/0896860819893558
6. In low and lower middle-income countries or regions,
every effort should be made to conform to the frame-
work of these statements, taking into account resource
limitations (practice point).
Liew A. Prescribing peritoneal dialysis and achieving
good quality dialysis in low and low-middle income
countries. Perit Dial Int. Epub ahead of print 2020.
DOI: 10.1177/0896860819894493
7. The principles of prescribing and assessing delivery of
high-quality PD to children are the same as for adults.
In all cases, the PD prescription should be designed to
meet the medical, psychosocial and financial needs of
the child and their family (practice point).
Warady BA, Schaefer F, Bagga A, et al. Prescribing
peritoneal dialysis for high quality care in children.
Perit Dial Int. Epub ahead of print 2020. DOI:
10.1177/0896860819893805
Brown et al. 5
Table 2. Summary of key points.
Topic Key points
Practice patterns from PDOPPS
PD prescription PD is prescribed in a variety of ways depending on local country resources, availability of PD
solutions and devices, modalities, reimbursement, clinicians’ preferences and other local
constraints, as well as patients’ characteristics and preferences regarding lifestyle and
family/caregiver wishes if providing assistance. (practice point)
Problems with using small solute clearance targets as sole measure of quality of PD
Critique of previous targets for small
solute clearance
1. There is very low certainty evidence that residual kidney function may be more important
than peritoneal clearance (practice point)
2. There appears to be no survival advantage in aiming routinely for a weekly Kt/V > 1.70
(practice point)
3. There is very low certainty evidence that a weekly Kt/V less than 1.7 may be associated
with increased morbidity (practice point)
Estimation of V: implications for Kt/V 1. In setting a Kt/V target for the individual patient, defining an acceptable range that
recognizes the uncertainty of the measurement, rather than applying a single cut-off value
is more appropriate (practice point)
2. Given the uncertainty of the estimation of V, clinicians should be encouraged to alter the
prescribed dialysis dose in response to patient’s symptoms, biochemical parameters and
treatment goals, rather than solely equating a single value cut-off value with adequate
treatment. (practice point)
3. When reporting prescribed dialysis dose at the population level, this should be as
population mean and range of Kt/V rather than as the proportion of patients who are
above an arbitrary cut-off value (e.g. 1.7); this will allow comparison at the population level
while recognizing limitations of the measurement (practice point)
Person-centred care
Person-centred PD delivery and
shared decision-making
1. The principles of person-centred care and shared decision-making should be applied to
the care of people who are reaching end-stage kidney disease (practice point)
2. People doing PD should be educated and given choice as far as is possible concerning the
PD prescription they receive (practice point)
3. People doing PD should be educated about their conditions and be informed about their
prognosis and given the opportunity to define their goals of care (practice point)
4. Patient reported experience of care is a crucial measure of how effective person centred
care is in PD and should be surveyed and used to improve the delivery of care (practice
point)
Other dialysis-related factors that should be measured
RKF 1. RKF is an important component of the overall well-being and survival of dialysis patients
(practice point)
2. There is low certainty evidence demonstrating that different PD modalities may make
little or no difference to preservation of RKF (practice point)
3. Caution should be taken to avoid volume depletion and hypotension based on low
certainty evidence that this may adversely affect RKF (practice point)
4. Urine output is increased by a variable, but small, amount when using neutral pH, low
glucose degradation product dialysate for the first 12–24 months after starting PD
(GRADE 1A), though there is low certainty evidence of associated reduction in
ultrafiltration
Volume status 1. High-quality PD prescription should aim to achieve and maintain clinical euvolemia while
taking residual kidney function and its preservation into account, so that both fluid
removal from peritoneal ultrafiltration and urine output are considered and residual
kidney function is not compromised (practice point)
2. Blood pressure should be included as one of the key objective parameters in assessing
quality of PD prescription. However, there is currently no evidence for a specific blood
pressure target in PD. (practice point)
3. Regular assessment of volume status including blood pressure and clinical examination
should be part of the routine clinical care. There is currently no clear evidence that
bioimpedance-guided fluid management leads to clinical benefits (practice point)
(continued)
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Table 2. (continued)
Topic Key points
Other factors beyond urea clearance 1. Patients who remain symptomatic despite a Kt/Vurea > 1.7 should have other dialysis and
non-dialysis-related factors considered as possible contributing factors. A trial of
increasing dialysis dose may be indicated (practice point)
2. Hypokalemia is associated with poor nutritional intake and adverse outcomes including
peritonitis. Dietary and/or oral potassium supplementation should be considered
(practice point)
3. Hypoalbuminemia is more common in PD compared to HD and is associated with protein
energy wasting and peritoneal protein losses. Interventions are of limited utility in
increasing serum albumin alone (practice point)
4. Hyperphosphatemia is multifactorial and associated with adverse outcomes in PD.
Dietary interventions, phosphate binders and modifying the PD prescription should be
considered to control hyperphosphatemia (practice point)
5. Poor nutritional status and protein energy wasting should be evaluated when assessing the
need to increase the dose of peritoneal dialysis (practice point)
Health-Related Quality of Life 1. Assessing the patient’s perception of their HRQOL should be integrated into routine care
assessments and taken into account when prescribing the optimal treatment regimen for
each patient (practice point)
2. Utilizing PROMs to assess patients’ experiences, symptoms and domains of difficulty
requires that appropriate approaches be utilized, such as the incorporation of various
questionnaires into routine patient care, addressing a wide variety of domains (practice
point)
3. It is suggested that PD regimen should be adjusted and modified using a person-centred,
shared decision-making individualized approach, based on patients’ symptoms and
medical/clinical needs, HRQOL, sense of well-being and satisfaction and life participation
with clearly defined goals of care (practice point)
Non-standard PD delivery
Incremental dialysis 1. Incremental peritoneal dialysis is a strategy by which less than standard ‘full-dose’ PD is
prescribed in people initiating PD; it is done with the intention of increasing the peritoneal
prescription if and when residual kidney clearance declines (DEFINITION)
2. Incremental PD strategies use less PD solution than standard full-dose PD prescription
and so cost less (GRADE 1A)
3. Incremental PD strategies achieve outcomes that are at least as good as full dose PD
prescription in patients with residual kidney function (practice point)
Frail and/or palliative patients 1. PD is only one component of overall care (practice point)
2. It is suggested that goals of care and care needs are determined after appropriate geriatric
and palliative care assessments with shared decision-making approach (practice point)
3. Management should consider people’s life goals, quality of life and symptom control
(practice point)
4. Residual kidney function enables PD prescription to be reduced; this enables reduction in
treatment burden in line with other existing multimorbidity guidelines (practice point)
Special situations
Prescribing PD in children 1. In children, selection of the dialysis modality should be based upon the child’s age and size,
presence of co-morbidities, family support available, modality contraindications, expertise
of the dialysis team and the child’s and parents’/caregivers’ choice. Preserving dialysis
access, both peritoneal and vascular access, must be considered when selecting the
optimal dialysis modality for a child (practice point)
2. While the goal of PD therapy is to optimize fluid management and solute clearance, this
must be considered in the context of the child’s and family’s expectations of dialysis and
quality of life, encouraging the child to participate at school and free time with family and
friends as much as possible (practice point)
PD in low and low middle-income
countries
1. The initial PD prescription should take into consideration the amount of residual renal
function and be aimed at achieving clinical euvolemia, clinical and biochemical well-being of
patients at the lowest cost, through the use of incremental PD with fewer bags and PD-
free days (practice point)
(continued)
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Key points from literature review
These recommendations include sections on delivering PD to
children and prescribing PD in lower income countries, so
that they are relevant for all people doing PD.The discussions
of the ISPD work group focused on the need for person-
centred care with an emphasis on dialysis-related factors that
impact on individualwell-being, PDdelivery approaches that
have evolved since 2006 (incremental PD, PD delivery to
older and frail individuals) and the problems associated with
interpreting Kt/V. The summary points and key recommen-
dations from each paper are summarized in Table 2.
Clinical use of recommendations
Which dialysis solution?
Peritoneal Diaysis Outcomes and Practice Patterns Study
(PDOPPS) data13 showed significant variations in the use
of different strengths of hypertonic glucose PD solutions,
icodextrin and neutral pH, low glucose degradation product
(GDP) solutions depending on availability and reimburse-
ment policies in different countries. Longer follow-up is
needed to determine the association between the use of
these solutions and patient outcomes. The ISPD cardiovas-
cular guideline published in 20159 recently reviewed the
evidence regarding icodextrin, neutral pH and low GDP
solutions; this has been updated by a Cochrane review
published in 2018.14
A. Once-daily icodextrin should be considered as an
alternative to hypertonic glucose solutions for long
dwells in people doing PD who are experiencing dif-
ficulties maintaining euvolemia due to insufficient
peritoneal ultrafiltration, taking into account the indi-
vidual’s peritoneal transport state (GRADE 1B).
B. Use of neutral pH, low GDP PD solutions improves
preservation of residual kidney function and urine
output (GRADE 1A). There is low certainty evi-
dence that use of these fluids may have little or no
effect on technique survival or mortality.
Identification of individuals who are ‘failing to thrive’
When prescribing person-centred high-quality PD, a chal-
lenge is to identify individuals who would benefit from an
increase in dialysis prescription or change in dialysis
Table 2. (continued)
Topic Key points
2. All efforts should be made to preserve residual kidney function and peritoneal membrane
function, and in so doing, maintain PD ultrafiltration for an extended period without the
need to intensify PD prescription (practice point)
3. Greater emphasis be made to utilize low-cost adjunctive management strategies in low
and low middle income countries (LLMICs), such as dietary and life-style modification, in
reducing the generation of uremic toxins and achieving euvolemia, with the aim to
minimize the need to intensify the PD prescription prematurely (practice point)
4. PET and weekly Kt/V should be encouraged if the cost of these tests do not compromise
the affordability of PD treatment in LLMICs. Where facility-performed PET or Kt/V is
unavailable or unaffordable, it is reasonable to assess quality and adequacy of PD
prescription based on clinical, biochemical parameters and clinical well-being of patients
(practice point)
5. PD programs should monitor the outcomes of these clinical interventions, focusing on
inexpensive clinical indicators, to determine efficacy, trends and progression and for
international comparison (practice point)
PDOPPS: Peritoneal Dialysis Outcomes and Practice Patterns Study; PD: peritoneal dialysis; RKF: residual kidney function; HRQOL: health-related
quality of life; PROM: patient-reported outcomes measures; PET: peritoneal equilibration test.
Table 3.Methods of recognising ‘failing to thrive’ patients on PD.
Factor Assessment methods
Poor patient well-being Ask the patient
Body weight changes (loss)
Clinical assessment
Hospitalization rate
Questionnaires to assess quality of
life, symptoms, depression
Poor volume control Clinical assessment
Blood pressure control
Recording of achieved ultrafiltration
by patient
Measurement of urine volume
Poor solute removal Blood tests
Small solute clearance (Kt/Vurea;
creatinine clearance)
Nutrition assessment
Non-dialysis factors:
comorbidities, frailty,
protein-energy wasting
Frailty assessment
Cognitive function assessment
Nutrition assessment
Hospitalization rate
PD: peritoneal dialysis.
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modality while recognizing that some individuals are reluc-
tant to do so. Furthermore, theremay be limitations to dialysis
delivery imposed by local healthcare structures and
resources. It is therefore important that all units develop some
local structures to identify individuals who are failing to
thrive on PD and to recognize the symptoms, clinical features
and biochemical markers that would support an increase in
dialysis prescription or change in dialysis modality. Methods
that could be used by care teams are suggested in Table 3.
The frequency of use of individual methods will depend
on local healthcare resources, but it is recommended that all
units develop some method of recognizing patients who
have symptoms or clinical features and biochemical mar-
kers indicating failure to thrive (practice point).
A person’s symptoms, clinical features and biochemical
markers that would support an increase in dialysis prescrip-
tion are shown in Table 4. We suggest that more than one of
these should be present given the inherent inaccuracies in
measuring small solute clearance and the potential multiple
causes of a single ‘uraemic’ symptom or biochemical
abnormality (practice point).
Involvement of people on PD with
guideline
Differences in healthcare resources and the heterogeneity
in PD technology, dialysis solutions availability and holis-
tic kidney care for people treated with dialysis have made it
difficult to have them involved at the guideline develop-
ment stage. The first version of this article was sent to
people doing PD from the various countries represented
by members of the guideline group. Feedback was given
by 22 people on peritoneal dialysis or caregivers from 8
countries on 5 continents and will be presented as a sepa-
rate accompanying paper. We have incorporated their wish
that ‘person’ is preferable to ‘patient’ in the revision of this
manuscript. We have also co-written a lay summary with a
UK group of people on dialysis with the key contributor
listed as an author.
Corbett RW, Fleisher G, Goodlet G, et al. International
Society for Peritoneal Dialysis Practice Recommenda-
tions: The view of the person who is doing or who has
done PD. Perit Dial Int. In press.
Implementation
It is not possible to embed an implementation plan into an
international guideline as the process will vary from country
to country depending on healthcare systems and resource
availability. We recommend strongly that people doing peri-
toneal dialysis are involved with national, regional and local
implementation plans based on this guideline.
Summary
Delivery of high-quality, goal-directed peritoneal dialysis
requires a person-centred, individualized shared decision-
making approach with tailoring of the prescription to the
person’s well-being, lifestyle and quality of life with
adjustments dependent on residual kidney function, volume
status and dialytic solute removal and to minimize treat-
ment burden. Given the minimal high-quality evidence for
the recommendations, it is essential to conduct further
research with questions prioritized by healthcare providers
and individuals with kidney disease.
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